Oncology

Pharmacy Times®, the leading multimedia resource for pharmacy professionals, is excited to announce Yale Cancer Center is now part of its Strategic Alliance Partnership program.

Interventions to reduce suffering, restore connections with others, and maintain safety are essential, and normalizing conversations about suicidal ideation and suicide itself is important.

The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma.

Data from a phase 1b/2 study investigating onvansertib as a treatment of KRAS-mutated mCRC demonstrated that 42% of patients achieved a PR and 67% demonstrated a durable response ranging from 6.1 months to 13.7 months.

Topics covered in-depth in the show include strategies for patient education, cancer team coordination, side effect monitoring and management of medications from both in-house and external specialty pharmacies.

HPV is the most common sexually transmitted infection, and if a high-risk infection does not go away, it can lead to the development of a variety of cancers, including 91% of all cervical cancers, 70% of oropharyngeal cancers, and cancers of the vulva, vagina, and penis and anus.

The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.

NCCN states that all patients with active cancer, or with active, recent, or planned cancer treatment, should be considered highest priority to receive one of the COVID-19 vaccines granted emergency use authorization.

The approval is for a 240 mg injection of nivolumab every 2 weeks or 480 mg every 4 weeks in combination with 40 mg once daily of cabozantinib.

Study finds that recurring glioblastoma tumors with very few mutations respond significantly better to immunotherapies than similar tumors with multiple mutations.

The study findings emphasize the need for people who missed or postponed a cancer screening test early in the pandemic to contact their health care provider to discuss the potential need to reschedule it, according to the study authors.

FDA grant priority review to a supplemental biologics license application for nivolumab (Opdivo) for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer.

Obstacles to cancer screenings for low-income patients can include lack of transportation and an inability to take time off of work.

Narsoplimab is an investigational, fully human IgG4 monoclonal antibody was designed to bind to mannan-binding lectin-associated serine protease-2

According to Senhwa Biosciences, the study’s findings indicate a clinically meaningful improvement in progression-free survival (PFS) (P

A minimally invasive, targeted treatment option, ImPACT is also under evaluation in patients with other localized tumors, such as urothelial cancer, esophageal cancer, lung cancer, and pancreatic cancer.

The FDA approved Enhertu in January 2020 for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

A survey found that the majority of oncologists did not feel like they could perform their duties as well as they could prior to the COVID-19 pandemic.

Novel program found cost effective and safe for patients with cancer managing the adverse effects of treatment.

Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.

Study finds the COVID-19 pandemic has drastically improved the quality and convenience of virtual cancer care.

Researchers from the University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.

According to research conducted at Rush University Medical Center, opioid use may increase patients’ risk of developing pancreatic cancer.

Verdinexor tablets are available only by prescription, and can be administered at home.

The FDA has granted fast track designations to cavrotolimod (AST-008) for use in combination with a PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma.

The Association of Community Cancer Centers offers virtual learning series.

Pvsripo is a novel immunotherapy that activates patients’ innate and adaptive immune system to enable anti-tumor response and establish immunologic memory to prevent the recurrence of cancer.

Darolutamide led to a 31% reduction in the risk of death, extending survival for patients with non-metastatic prostate cancer.